Daewon Pharmaceutical Co., Ltd. (003220.KS)
KRW 14020.0
(-1.2%)
KRW 14020.0
(-1.2%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 221.99 Billion KRW | 13.88% |
| 2022 | 194.93 Billion KRW | 24.13% |
| 2021 | 157.04 Billion KRW | 10.72% |
| 2020 | 141.83 Billion KRW | -2.21% |
| 2019 | 145.04 Billion KRW | 7.65% |
| 2018 | 134.74 Billion KRW | 6.31% |
| 2017 | 126.74 Billion KRW | 16.96% |
| 2016 | 108.36 Billion KRW | 15.2% |
| 2015 | 94.06 Billion KRW | 14.02% |
| 2014 | 82.49 Billion KRW | 18.75% |
| 2013 | 69.46 Billion KRW | 17.65% |
| 2012 | 59.04 Billion KRW | -7.5% |
| 2011 | 63.83 Billion KRW | -3.7% |
| 2010 | 66.29 Billion KRW | 15.42% |
| 2009 | 57.43 Billion KRW | 19.02% |
| 2008 | 48.25 Billion KRW | 18.76% |
| 2007 | 40.62 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 64.17 Billion KRW | 1.93% |
| 2024 Q2 | 63.61 Billion KRW | 0.86% |
| 2023 Q3 | -53.26 Billion KRW | 3.92% |
| 2023 Q2 | -55.43 Billion KRW | -206.25% |
| 2023 Q1 | 52.17 Billion KRW | -8.21% |
| 2023 FY | 221.99 Billion KRW | 13.88% |
| 2023 Q4 | 62.95 Billion KRW | 218.2% |
| 2022 Q1 | 44.05 Billion KRW | 14.02% |
| 2022 FY | 194.93 Billion KRW | 24.13% |
| 2022 Q2 | 47.76 Billion KRW | 8.41% |
| 2022 Q3 | 46.26 Billion KRW | -3.13% |
| 2022 Q4 | 56.84 Billion KRW | 22.87% |
| 2021 FY | 157.04 Billion KRW | 10.72% |
| 2021 Q1 | 40.96 Billion KRW | 2.47% |
| 2021 Q2 | 40.35 Billion KRW | -1.49% |
| 2021 Q4 | 38.64 Billion KRW | 4.2% |
| 2021 Q3 | 37.08 Billion KRW | -8.1% |
| 2020 Q1 | 34.69 Billion KRW | -12.15% |
| 2020 Q4 | 39.97 Billion KRW | 14.33% |
| 2020 Q3 | 34.96 Billion KRW | 8.57% |
| 2020 FY | 141.83 Billion KRW | -2.21% |
| 2020 Q2 | 32.2 Billion KRW | -7.19% |
| 2019 Q3 | 34.37 Billion KRW | -3.5% |
| 2019 FY | 145.04 Billion KRW | 7.65% |
| 2019 Q2 | 35.62 Billion KRW | 0.18% |
| 2019 Q4 | 39.49 Billion KRW | 14.9% |
| 2019 Q1 | 35.55 Billion KRW | -4.1% |
| 2018 Q3 | 30.84 Billion KRW | -8.49% |
| 2018 FY | 134.74 Billion KRW | 6.31% |
| 2018 Q1 | 33.1 Billion KRW | -9.0% |
| 2018 Q4 | 37.07 Billion KRW | 20.2% |
| 2018 Q2 | 33.7 Billion KRW | 1.82% |
| 2017 Q1 | 29.61 Billion KRW | -1.8% |
| 2017 Q4 | 36.37 Billion KRW | 19.77% |
| 2017 FY | 126.74 Billion KRW | 16.96% |
| 2017 Q3 | 30.37 Billion KRW | -0.01% |
| 2017 Q2 | 30.37 Billion KRW | 2.58% |
| 2016 FY | 108.36 Billion KRW | 15.2% |
| 2016 Q2 | 27.16 Billion KRW | 3.35% |
| 2016 Q1 | 26.28 Billion KRW | 8.32% |
| 2016 Q3 | 24.75 Billion KRW | -8.9% |
| 2016 Q4 | 30.16 Billion KRW | 21.86% |
| 2015 FY | 94.06 Billion KRW | 14.02% |
| 2015 Q1 | 23.64 Billion KRW | 3.94% |
| 2015 Q4 | 24.26 Billion KRW | 3.88% |
| 2015 Q3 | 23.36 Billion KRW | 2.49% |
| 2015 Q2 | 22.79 Billion KRW | -3.58% |
| 2014 Q2 | 20.02 Billion KRW | -1.56% |
| 2014 Q1 | 20.34 Billion KRW | 10.29% |
| 2014 FY | 82.49 Billion KRW | 18.75% |
| 2014 Q4 | 22.74 Billion KRW | 17.36% |
| 2014 Q3 | 19.37 Billion KRW | -3.23% |
| 2013 Q2 | 16.07 Billion KRW | -9.58% |
| 2013 Q3 | 17.16 Billion KRW | 6.75% |
| 2013 Q4 | 18.44 Billion KRW | 7.48% |
| 2013 FY | 69.46 Billion KRW | 17.65% |
| 2013 Q1 | 17.78 Billion KRW | 17.85% |
| 2012 Q3 | 14.1 Billion KRW | -3.92% |
| 2012 Q4 | 15.08 Billion KRW | 6.95% |
| 2012 FY | 59.04 Billion KRW | -7.5% |
| 2012 Q1 | 14.74 Billion KRW | 0.0% |
| 2012 Q2 | 14.68 Billion KRW | -0.44% |
| 2011 Q1 | 14.84 Billion KRW | -21.25% |
| 2011 Q2 | 16 Billion KRW | 7.77% |
| 2011 Q3 | 14.14 Billion KRW | -11.6% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 FY | 63.83 Billion KRW | -3.7% |
| 2010 Q2 | 17.04 Billion KRW | 8.21% |
| 2010 Q1 | 15.75 Billion KRW | -7.49% |
| 2010 FY | 66.29 Billion KRW | 15.42% |
| 2010 Q3 | 14.65 Billion KRW | -13.98% |
| 2010 Q4 | 18.85 Billion KRW | 28.64% |
| 2009 Q4 | 17.02 Billion KRW | 25.99% |
| 2009 FY | 57.43 Billion KRW | 19.02% |
| 2009 Q3 | 13.51 Billion KRW | -2.48% |
| 2009 Q2 | 13.85 Billion KRW | 5.69% |
| 2009 Q1 | 13.11 Billion KRW | 7.92% |
| 2008 Q3 | 13.01 Billion KRW | 8.8% |
| 2008 Q2 | 11.96 Billion KRW | 7.5% |
| 2008 Q1 | 11.12 Billion KRW | -9.73% |
| 2008 FY | 48.25 Billion KRW | 18.76% |
| 2008 Q4 | 12.14 Billion KRW | -6.66% |
| 2007 FY | 40.62 Billion KRW | 0.0% |
| 2007 Q4 | 12.32 Billion KRW | 29.48% |
| 2007 Q3 | 9.52 Billion KRW | -4.65% |
| 2007 Q2 | 9.98 Billion KRW | 13.49% |
| 2007 Q1 | 8.79 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -369.8% |
| Dong-A Socio Holdings Co., Ltd. | 297.99 Billion KRW | 25.502% |
| Ildong Holdings Co., Ltd. | 278.43 Billion KRW | 20.27% |
| HANDOK Inc. | 153.76 Billion KRW | -44.372% |
| Kukje Pharma Co., Ltd. | 69.21 Billion KRW | -220.745% |
| Yuhan Corporation | 489.94 Billion KRW | 54.689% |
| Dong-A ST Co., Ltd. | 306.95 Billion KRW | 27.678% |
| SAMSUNG PHARM. Co., LTD. | 41.78 Billion KRW | -431.231% |
| Hanmi Pharm. Co., Ltd. | 610.97 Billion KRW | 63.665% |
| Hanall Biopharma Co.,Ltd | 71.98 Billion KRW | -208.403% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | -27.477% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.05 Billion KRW | -454.261% |
| MYUNGMOON Pharm co.,Ltd | 93.55 Billion KRW | -137.301% |
| Hana Pharm Co., Ltd. | 114.72 Billion KRW | -93.505% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -369.8% |
| Ilsung Pharmaceuticals Co., Ltd. | 42.47 Billion KRW | -422.698% |
| REYON Pharmaceutical Co., Ltd. | 75.04 Billion KRW | -195.804% |
| Aprogen pharmaceuticals,Inc. | 58.64 Billion KRW | -278.552% |
| JW Holdings Corporation | 301.25 Billion KRW | 26.309% |
| Ildong Pharmaceutical Co., Ltd. | 260.95 Billion KRW | 14.929% |
| Chong Kun Dang Pharmaceutical Corp. | 408.65 Billion KRW | 45.676% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 7.079% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | -73.886% |
| Hyundai Pharmaceutical Co., Ltd. | 68.31 Billion KRW | -224.983% |
| Samil Pharmaceutical Co.,Ltd | 65.75 Billion KRW | -237.634% |
| Jeil Pharmaceutical Co.,Ltd | 174.92 Billion KRW | -26.91% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -369.8% |
| Kwang Dong Pharmaceutical Co., Ltd. | 249.12 Billion KRW | 10.888% |
| Daewoong pharmaceutical Co.,Ltd | 560.43 Billion KRW | 60.388% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 7.079% |
| Yuhan Corporation | 489.94 Billion KRW | 54.689% |
| Jeil Pharma Holdings Inc | 193.66 Billion KRW | -14.631% |
| Yungjin Pharm. Co., Ltd. | 69.46 Billion KRW | -219.567% |
| Suheung Co., Ltd. | 56.03 Billion KRW | -296.2% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 7.079% |
| Samjin Pharmaceuticals Co., Ltd. | 126.39 Billion KRW | -75.642% |
| Korea United Pharm Inc. | 118.21 Billion KRW | -87.794% |
| CKD Bio Corp. | 25.19 Billion KRW | -781.096% |
| Dongwha Pharm.Co.,Ltd | 165.11 Billion KRW | -34.452% |
| Whan In Pharm Co.,Ltd. | 66.41 Billion KRW | -234.248% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | -73.886% |
| Chong Kun Dang Holdings Corp. | 350.71 Billion KRW | 36.701% |
| Boryung Corporation | 285.16 Billion KRW | 22.15% |
| Bukwang Pharmaceutical Co., Ltd. | 87.54 Billion KRW | -153.591% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | -27.477% |
| JW Lifescience Corporation | 20.26 Billion KRW | -995.664% |